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Introduction
Cellular quality control pathways monitor protein folding and 
target flawed products for turnover. In the secretory pathway, 
ER quality control (ERQC) mechanisms must also regulate traf-
ficking to prevent the premature export of misfolded proteins. 
Proteins deemed misfolded are routed to ER-associated degra-
dation (ERAD) pathways. These pathways are defined by spe-
cialized E3 ubiquitin ligases that organize factors to receive and 
extract polypeptides from the ER membrane. On the cytosolic 
face, substrates are ubiquitinated and degraded by the 26S 
proteasome (Sifers, 2003; Sitia and Braakman, 2003; Römisch, 
2005; Vembar and Brodsky, 2008).
In budding yeast, the Hrd1p and Doa10p ubiquitin ligases 
represent two distinct pathways (Huyer et al., 2004; Vashist and 
Ng, 2004; Carvalho et al., 2006). Metazoans have homologues 
of these E3s and have also evolved an expanded repertoire of 
ERAD-processing  centers  (for  review  see  Nakatsukasa  and 
Brodsky, 2008). Of the yeast ERAD-processing sites, the Doa10 
complex is the simplest. At Doa10 sites, substrate ubiquitina-
tion  is  mediated  by  the  E2  ubiquitin–conjugating  enzyme 
Ubc7p, which is attached to Doa10p via Cue1p. The Cdc48p 
(p97  in  mammals)–Npl4p–Ufd1p  subcomplex  is  linked  via 
Ubx2p and extracts substrates from the membrane (Ye et al., 
2001;  Rabinovich  et  al.,  2002;  Lilley  and  Ploegh,  2004; 
Schuberth and Buchberger, 2005; Carvalho et al., 2006; Gauss 
et al., 2006b). Doa10p clients include folded cytosolic proteins 
and membrane proteins bearing misfolded cytosolic domains 
(ERAD-C; Swanson et al., 2001; Huyer et al., 2004; Vashist and 
Ng, 2004; Ravid et al., 2006; Metzger et al., 2008). The Hrd1 
complex contains all known partners of Doa10p and several more. 
Directly bound to Hrd1p is Hrd3p, a tetratricopeptide repeat–
containing protein involved in substrate binding (Gardner et al., 
2000; Denic et al., 2006; Gauss et al., 2006b). Associated with 
Hrd3p (SEL1L in mammals) is the lectin-like factor Yos9p   
(OS-9 and XTP3-B in mammals; Carvalho et al., 2006; Denic   
et al., 2006; Mueller et al., 2006; Christianson et al., 2008;   
Hosokawa et al., 2008). Yos9p is the receptor for glycans con-
taining a terminal 1,6-linked mannose generated by Htm1p 
(also known as Mnl1p; Nakatsukasa et al., 2001; Olivari et al., 
2006; Hosokawa et al., 2007; Quan et al., 2008; Clerc et al., 
2009). Htm1p is the final enzyme of a glycan-trimming cascade 
that forms the basis of a de facto folding timer. Unfolded pro-
teins modified by Htm1p display an ERAD signal comprised of 
the glycan and adjacent unfolded peptide segment (Xie et al., 
2009). This pathway has been termed ERAD-L because it   
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ecretory protein folding is monitored by endo-
plasmic reticulum (ER) quality control mechanisms. 
Misfolded proteins are retained and targeted to   
ER-associated  degradation  (ERAD)  pathways.  At  their 
core are E3 ubiquitin ligases, which organize factors that 
recognize, ubiquitinate, and translocate substrates. Of 
these, we report that the Hrd1 complex manages three 
distinct substrate classes. A core complex is required for 
all classes and is sufficient for some membrane proteins. 
The accessory factors Usa1p and Der1p adapt the com-
plex to process luminal substrates. Their integration is suf-
ficient to process molecules bearing glycan-independent 
degradation signals. The presence of Yos9p extends the 
substrate range by mediating the recognition of glycan-
based degradation signals. This modular organization 
enables  the  Hrd1  complex  to  recognize  topologically   
diverse substrates. The Hrd1 system does not directly eval-
uate the folding state of polypeptides. Instead, it does so 
indirectly, by recognizing specific embedded signals dis-
played upon misfolding.
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In this study, we report that the yeast Hrd1 complex has 
the capacity to process three substrate classes. The pattern of 
substrate specialization among components reveals functional 
modularity in its organization. At the most basic level is a core 
complex whose factors are required for all substrates. These   
are comprised of factors common to both Doa10 and Hrd1 com-
plexes. The integration of accessory factors Usa1p and Der1p 
expands the client pool to include luminal proteins. The addi-
tion of another factor, Yos9p, adapts the complex to recognize 
misfolded glycoproteins vetted through a glycan timer mecha-
nism. Importantly, we demonstrate that utilization of luminal 
pathways is specified by signals embedded in proteins that are 
displayed only when misfolded. Together, these data show that 
the  Hrd1  E3  complex  manages  distinct  substrate  classes  by   
assimilating factors that diversify signal recognition.
Results
Novel PrA variants reveal a third substrate 
class of the yeast Hrd1 complex
A folding defective mutant of the vacuolar proteinase A (PrA) 
called PrA*-Ab is a glycan-dependent substrate of the ERAD-L 
pathway (Fig. 1 A; Finger et al., 1993; Spear and Ng, 2005). 
Deletion analysis identified two variants, PrA*-Ab147–183 
and  PrA*-Ab295–331,  degraded  rapidly  with  a  reduced   
dependence on Htm1p, suggesting a glycan-independent mode   
of ERAD-L (Fig. S1; Xie et al., 2009). To confirm the assertion, 
a nonglycosylated PrA (ngPrA) variant called ngPrA*295–
331 (Fig. 1 A) was tested. Its rapid degradation in control cells 
and stability in hrd1 cells demonstrate the existence of the 
pathway in budding yeast (Fig. 1 B). As expected, cells lack-
ing  HTM1  failed  to  retard  its  degradation  and  even  slightly 
accelerated it (Fig. 1 B). For this pathway, the 295–331   
detects misfolded luminal domains (Vashist and Ng, 2004).   
Two additional factors of the Hrd1 complex, Usa1p (HERP in 
mammals) and Der1p (Derlin-1 in mammals), are required for 
ERAD-L (Knop et al., 1996a; Lilley and Ploegh, 2004; Ye et al., 
2004; Carvalho et al., 2006; Okuda-Shimizu and Hendershot, 
2007). The Hrd1p complex also detects proteins with misfolded 
membrane segments through a mode termed ERAD-M (ERAD 
membrane; Carvalho et al., 2006).
Together, these systems appear to account for the quality 
control mechanisms for nascent polypeptides that traffic through 
the ER and provide a unifying model for ERAD, at least in 
budding yeast (Carvalho et al., 2006). However, one sub-
strate class, nonglycosylated soluble proteins, seems to fall 
outside of this framework. A nonglycosylated variant of the 
mating pheromone precursor, gppF, is retained in the ER 
and degraded by the proteasome (McCracken and Brodsky, 
1996). Unlike other known ERAD substrates, degradation is 
independent of ubiquitination and all known components of 
the E3 complexes (Brodsky and McCracken, 1999). Cholera 
toxin and the ricin A chain may hijack a similar ubiquitin- 
independent mechanism for translocation from the ER to the 
cytosol (Simpson et al., 1999; Rodighiero et al., 2002). In con-
trast, the mammalian Hrd1 pathway degrades unassembled 
immunoglobulin  light chain and the NHK-QQQ variant of 
1-antitrypsin, both of which are nonglycosylated soluble pro-
teins (Okuda-Shimizu and Hendershot, 2007; Hosokawa et al., 
2008). Required components for their degradation include 
Hrd1, p97, Derlin-1, Herp, and XTP3-B. In a mammalian cell-
free system, gppF retrotranslocation does not require the 
activity of p97 but requires Derlin-1, a member of the Hrd1 
complex (Wahlman et al., 2007). Do these findings indicate   
an evolutionary divergence for how this substrate class is de-
graded in mammals?
Figure 1.  ngPrA variants are substrates of the 
Hrd1p-dependent ERAD pathway. (A) Schematic 
representation of PrA variants with positions of 
deletions under each diagram. N-linked glycans 
are represented by branched symbols, signal 
sequences are shown in dark gray, prodomains 
are colored light gray, and HA epitope tags 
are indicated. PrA* differs from PrA by lack-
ing sequences Leu55 through Tyr91. (B) Wild-
type (WT), hrd1, and htm1 cells expressing 
ngPrA*295–331  were  pulse  labeled  for   
10 min with [
35S]methionine/cysteine at 30°C 
followed by a cold chase for the times indicated. 
Immunoprecipitation of ngPrA*295–331 was 
performed  using  anti-HA  mAb  and  resolved 
by SDS-PAGE. Decay kinetics were quantified 
by phosphorimager analysis. The data reflect 
three independent experiments with the SEM in-
dicated by error bars. Representative phosphor 
scan images are shown. (C) Wild-type, hrd1, 
and htm1 cells expressing ngPrA295–331 
were  analyzed  by  pulse-chase  analysis  as   
described in B. (D) Intracellular localization of 
ngPrA295–331 in hrd1 cells was analyzed 
by indirect immunofluorescence. The substrate 
was detected using anti-HA antibodies (green), 
the ER was visualized using anti-Kar2p antisera 
(red), and the positions of nuclei were stained 
by DAPI. Bar, 2 µM.709 Modularity of an ERAD receptor complex • Kanehara et al.
degradation  in  the  yos9-R200A  variant  (Bhamidipati  et  al., 
2005). In this strain, a conserved residue required for glycan 
recognition is mutated. By pulse-chase analysis, the degrada-
tion  defect  of  PrA*-Ab  (glycan-dependent  substrate)  in  the 
yos9-R200A strain is equal to yos9, demonstrating the effi-
cacy of the point mutation (Fig. 3 E). In contrast, ngPrA295–
331 turnover in the yos9-R200A was as efficient as wild type 
(Fig. 3 F). Collectively, the profile of ngPrA295–331 degra-
dation mirrors that of misfolded glycoproteins, except Htm1p 
and Yos9p are dispensable (Table I). Although they are estab-
lished mediators of glycan-based ERAD, these data provide 
new evidence of their functional specificity.
ngPrA295–331 competes with the glycan-
dependent substrate CPY* for degradation
A previous study provided evidence of Hrd1 subcomplexes, dif-
fering only by the occupancy of Yos9p (Gauss et al., 2006a). 
Combined with the results presented in this study, the data raise 
lesion alone is sufficient to cause glycan-independent degrada-
tion of PrA. The variant ngPrA295–331 (Fig. 1 A) that lacks 
the “star” deletion (amino acids 55–91) behaved identically 
(Fig. 1 C). Substrates of ERQC are typically retained in the ER   
even if degradation is blocked (Gething et al., 1986; de Silva 
et al., 1990; Loayza et al., 1998). Using indirect immuno-
fluorescence, ngPrA295–331 colocalized with the ER marker 
Kar2p in hrd1 cells, confirming it as a bona fide substrate of 
ERQC (Fig. 1 D).
To identify direct interactors of ngPrA295–331, the sub-
strate was purified from a microsomal fraction under non-
denaturing conditions. A major species migrating near the 75-kD 
marker was identified as the ER chaperone Kar2p (BiP) by mass 
spectrometry (Fig. 2 A and Table S1). To test the requirement of 
the chaperone in the glycan-independent mode of the Hrd1 path-
way, ngPrA295–331 turnover was analyzed in the kar2-1 and 
scj1jem1 mutants. The kar2-1 allele disrupts ERAD without 
affecting Kar2p’s essential housekeeping functions (Kabani   
et al., 2003). Scj1p and Jem1p are ER DnaJ family proteins   
that functionally interact with Kar2p (Silberstein et al., 1998; 
Nishikawa et al., 2001). Likely because of redundancy, SCJ1 and 
JEM1 single mutants display weak and no ERAD phenotypes, 
respectively, whereas the double mutant is strongly defective 
(Nishikawa et al., 2001). ngPrA295–331 is strongly stabilized 
in both strains, demonstrating a critical role of the chaperone 
system in glycan-independent ERAD (Fig. 2, B and C).
The glycan-independent luminal pathway 
requires most but not all factors of the 
Hrd1 ERAD system
We next determined the factors of the Hrd1 complex required to 
recognize and degrade ngPrA295–331. This analysis extends 
the important mammalian findings by providing a more com-
prehensive accounting of relevant factors (Okuda-Shimizu and 
Hendershot, 2007; Hosokawa et al., 2008). First, functions in 
common with the Doa10 complex were tested. ngPrA295–331 
is strongly stabilized in cdc48-1 and cue1 strains, indicating 
that its degradation follows a classical ERAD mechanism (Fig. 3, 
A and B).
Next, genes encoding components exclusive to the Hrd1 
complex  were  examined.  Pulse-chase  analysis  shows  that 
DER1 and USA1 are also essential for ngPrA295–331 degra-
dation (Fig. 3 C). The analysis was not performed for Hrd3p 
because its presence is required for Hrd1p stability (Gardner   
et al., 2000). In contrast, degradation of ngPrA295–331 is   
efficient in a strain deleted of YOS9 (Fig. 3 D). This differs 
from glycan-dependent substrates, which depend heavily on 
Yos9p for degradation (Buschhorn et al., 2004; Bhamidipati   
et al., 2005; Kim et al., 2005; Szathmary et al., 2005). Never-
theless, we did observe slight stabilization over wild type. 
We wondered whether this result reflects a possible role in the   
glycan-independent  pathway.  In  mammals,  reduction  of  the 
Yos9 homologue hXTP3-B (long form) stabilizes the non-
glycosylated NHK-QQQ substrate (Hosokawa et al., 2008). 
Alternatively, the effect we observed could be indirect, caused 
structurally by physically eliminating a member of the com-
plex. To confirm or rule out the latter possibility, we analyzed 
Figure 2.  The Kar2 chaperone system is required for glycan-independent 
ERAD-L. (A) ngPrA295–331 protein complexes purified from microsomes 
were resolved by SDS-PAGE and visualized by Coomassie brilliant blue. 
The band labeled Kar2p was excised and identified by mass spectrom-
etry (Table S1). The asterisk indicates the position of IgG heavy chain.   
(B  and  C)  Wild-type  (WT),  kar2-1,  and  scj1jem1  cells  expressing   
ngPrA295–331 were analyzed by metabolic pulse-chase analysis as de-
scribed in Fig. 1 B. The plotted data reflect three independent experiments 
with the SEM indicated by error bars.JCB • VOLUME 188 • NUMBER 5 • 2010   710
and Wolf, 2005; Spear and Ng, 2005). To identify a glycan-
independent determinant, we started with our shortest variant, 
PrA*-Ab147–183/295–331  (Fig.  S1  E),  and  eliminated  its 
remaining  glycan  to  generate  PrA*-GI  (glycan  independent; 
Fig. 5 A). As shown in Fig. 5 B, its degradation profile shows 
that it is a substrate of ERAD. A systematic deletion series was 
generated for PrA*-GI to identify essential ERAD determinants 
if they exist (Fig. 5 A). Deleting any of its three N-proximal 
segments had little effect on degradation (Fig. 5 C). This in-
cludes PrA*-GI2, which eliminated the peptide portion of the 
glycan-dependent determinant (Xie et al., 2009). Deletion of 
the C-terminal segment, however, strongly stabilized the mole-
cule, indicating that an important element was altered (Fig. 5 C,   
PrA*-GI4). However, PrA*-GI4 is less stable than PrA*-
GI in ERAD mutants (Fig. 5, compare C with B), suggesting   
the possible presence of a second, less-important determinant 
elsewhere in PrA.
By analogy to glycan-dependent signals, if the deletion 
specifically  removed  a  degradation  signal,  PrA*-GI4  is   
expected to be retained stably in the ER as a misfolded protein. 
Alternatively, mislocalization or the formation of a structure   
incompatible  with  ERAD  could  explain  the  phenotype.  To   
address these possibilities, two experiments were performed. 
Indirect immunofluorescence shows that PrA*-GI4 colocal-
izes with the ER marker Kar2p (Fig. 5 D). This result shows that 
the molecule is retained by ERQC but incompetent for ERAD. 
To assess whether PrA*-GI4 generated a molecule generally 
the intriguing possibility of distinct receptor sites devoted to 
glycosylated and nonglycosylated substrates. We applied an in 
vivo substrate competition assay to test the possibility. CPY* 
regulated by the inducible GAL1 promoter was selected as the 
glycan-dependent competitor (Johnston and Davis, 1984; Knop 
et al., 1996b). Test proteins were constitutively expressed from 
their native promoters, and turnover was monitored by meta-
bolic pulse-chase analysis. As expected, CPY* competes with 
PrA*-Ab, the glycan-dependent control (Fig. 4 A). When the 
assay was applied to ngPrA295–331, a similar reduction was 
observed, indicating that the two substrate classes compete in 
ERAD (Fig. 4 B). To determine whether competition is specific 
to the Hrd1p complex or includes general factors of ERAD, the 
assay was repeated with the Doa10p-dependent substrate Ste6-
166p. In this study, Ste6-166p degradation was as efficient as 
the negative control after a slight delay at the first chase point 
(Fig. 4 C). These data show that the two luminal substrate 
classes can compete for the same Hrd1 complexes.
The glycan-independent mode of ERAD-L 
recognizes distinct degradation signals
The classical ERAD substrates CPY* and PrA* contain bi-
partite degradation signals composed of specific glycans and 
their adjacent unfolded peptide segments (Quan et al., 2008; 
Clerc et al., 2009; Xie et al., 2009). Without these glycans, the 
molecules are stable, suggesting that the remaining segments 
are  not  recognized  by  a  glycan-independent  mode  (Kostova 
Figure  3.  ngPrA295–331  degradation  re-
quires multiple components of the Hrd1 complex. 
Metabolic  pulse-chase  experiments  were  per-
formed and presented as in Fig. 1 B. Strains and 
substrates are indicated. (A) Wild-type (WT) and 
cdc48-1 cells expressing ngPrA295–331 were 
grown to log phase at 25°C and shifted to 30°C 
for 30 min before the experiment. (B) Wild-type 
and cue1 cells expressing ngPrA295–331. 
(C) Wild-type, der1, and usa1 cells express-
ing ngPrA295–331. (D) Wild-type and yos9 
cells expressing ngPrA295–331. (E) Wild-type,   
yos9,  and  yos9-R200A  cells  expressing 
PrA*-Ab. (F) Wild-type, yos9, and yos9-R200A 
cells expressing ngPrA295–331. Error bars in-
dicate SEM.
Table I.  Genetic requirements for the degradation of Hrd1-dependent substrates
Substrate HRD1 CUE1 CDC48 USA1 DER1 YOS9 HTM1
CPY*, PrA* + + + + + + +
ngPrA295–331 + + + + +  
Hmg2p + + +    711 Modularity of an ERAD receptor complex • Kanehara et al.
Their inclusion is sufficient for the Hrd1 complex to process   
luminal  substrates  bearing  glycan-independent  determinants.   
An important function of Usa1p is to link Der1p to the Hrd1 
complex (Carvalho et al., 2006; Horn et al., 2009). Although 
Sec61-2p and Hmg2p (single Myc tagged) are efficiently de-
graded in the absence of Usa1p, recent studies have shown that it 
is not dispensable for all membrane substrates (Horn et al., 2009; 
Carroll and Hampton, 2010). Their data suggest that Usa1p may 
also play a broader role in maintaining the integrity of the Hrd1 
complex. Although the precise role of Der1p remains unclear, 
the prevailing evidence suggests that it facilitates the move-
ment of luminal domains to the cytosol. The mammalian Der1p   
homologue Derlin-1 is in proximity to MHC class I molecules 
during  retrotranslocation  across  ER  membranes  (Lilley  and 
Ploegh, 2004; Ye et al., 2004). This makes Derlin-1 a candidate 
component of the ERAD translocation pore. Although a role in 
signal recognition isn’t ruled out for Der1p and Usa1p, Hrd3p 
more likely plays this role in ERAD-L (in addition to Yos9p).   
incapable of entering ERAD, the A glycosylation site was   
restored to reconstitute the original glycan-dependent signal. 
The resulting molecule, PrA*-GI4CHO (Fig. 5 A), degraded 
rapidly in an HTM1-dependent fashion (Fig. 5 E). This supports 
the conclusion that the 4 lesion eliminated a critical degrada-
tion signal. To determine whether the element is sufficient to 
signal glycan-independent degradation, the C-terminal domain 
(CTD) containing this domain was expressed behind the PrA 
signal  sequence  (Fig.  5  A,  PrA-CTD).  The  ngPrA-CTD  is   
degraded rapidly in wild-type cells and strongly stabilized in 
hrd1, usa1, and der1 strains, confirming that it uses the 
Hrd1 pathway (Fig. 5 F). As expected, PrA-CTD degradation is 
efficient in cells lacking HTM1 or YOS9 (Fig. 5 G). This result 
confirms that the Hrd1 complex can efficiently process non-
glycosylated luminal substrates in the absence of Yos9p. These 
data show that determinants recognized by the glycan-dependent 
and -independent modes of the Hrd1p complex can be nonover-
lapping and distinct within the same molecule.
Discussion
The Hrd1 complex is functionally  
modular in its management of three 
substrate classes
This study extends the known Hrd1 client range in budding 
yeast and demonstrates that the surveillance of glycosylated   
and nonglycosylated luminal substrates by the Hrd1 complex is 
conserved. Based on these results, we questioned how a single 
complex could manage such a diverse range of substrates. An 
interesting pattern emerges from comparison of data from previous 
studies and this study (Table I; Bays et al., 2001; Carvalho et al., 
2006; Sato et al., 2009). ERAD-M substrates like Sec61-2p and 
Hmg2p have the simplest requirements for substrate recogni-
tion and degradation. These include the Hrd1/Hrd3 E3 dimer, 
the  E2  dimer  (Cue1p/Ubc7p),  and  the  Cdc48p  subcomplex 
(Cdc48p–Npl4p–Ufd1p–Ubx2p; Fig. S2). These components, 
which are interchangeable between the Hrd1 and Doa10 com-
plexes, are required for all identified ubiquitin-dependent ERAD 
substrates thus far. Adding Der1p and Usa1p to the complex 
expands the Hrd1 range to handle luminal substrates bearing 
specific peptide signals. The additional presence of Yos9p 
endows the capacity to recognize glycan signals marking sub-
strates whose time windows for folding have expired (Quan   
et al., 2008; Clerc et al., 2009).
The primary functions of ERAD E3 complexes include 
substrate sorting, ubiquitination, and membrane extraction. By 
extension, the Hrd1 core complex might be sufficient to carry 
out these activities for ERAD-M. Recently, a systematic study 
revealed that Hrd1p transmembrane segments detect structural 
deviations  in  substrate  transmembrane  domains  (Sato  et  al., 
2009). This suggests that Hrd1p itself recognizes degradation 
signals for this class. With the source of ubiquitination and sub-
strate extraction activities already known, this study explains 
why components outside the core can be dispensable for some 
substrates of this class. The accessory factors Der1p and Usa1p 
are required for all substrates of the Hrd1 pathway bearing lumi-
nal lesions (Fig. 3 C; Knop et al., 1996a; Carvalho et al., 2006). 
Figure  4.  Glycan-independent  and  glycan-dependent  substrates  of 
ERAD-L are competitors for degradation. (A) Wild-type cells carrying GAL1-
  regulated CPY* (or nonexpressing control vector) and PrA*-Ab regulated 
by its native promoter were shifted to galactose media to induce CPY* 
expression. Turnover of PrA*-Ab was analyzed as described in Fig. 1 B.   
(B) The experiment was performed as described for A with ngPrA295–
331 as the test substrate. (C) The experiment was performed as described 
for A with Ste6-166p as the test substrate. OE, overexpression. Error bars 
indicate SEM.JCB • VOLUME 188 • NUMBER 5 • 2010   712
and terminally misfolded proteins. It is now well established 
that glycoprotein substrates can display highly specific sig-
nals for degradation. Normally, N-linked glycans of nascent 
polypeptides are progressively trimmed in the ER by gluco-
sidase I, glucosidase II, and -mannosidase I to the GlcNAc2Man8 
structure. Should a molecule fail to fold at this point, the 
Htm1p mannosidase cleaves a single residue to expose a ter-
minal 1,6-linked mannose, the ligand for the Yos9p recep-
tor (Quan et al., 2008; Clerc et al., 2009). This combines 
with adjacent disordered peptide segments to form a bipar-
tite ERAD determinant (Xie et al., 2009). PrA may form a 
class of substrates that harbor determinants for both modes 
of the Hrd1 complex. Our analyses show that the PrA glycan-
independent determinant is located in a region distinct from 
its glycan-dependent determinant (Fig. 5). These experiments 
show that protein misfolding is not inherently sufficient to 
trigger ERAD. Instead, ERAD responds to specific cues in 
substrates that coevolved with the system. This might explain 
why yeast and mammalian ERAD pathways are sometimes 
unable to recognize misfolded proteins from other organisms 
(Hong et al., 1996; Mancini et al., 2003; Coughlan et al., 
2004). Although much of the general mechanisms are con-
served, the specific nature of some signals may have diverged.
The novel PrA variants demonstrate the conservation of 
the ubiquitin–proteasome system in the quality of control of 
soluble nonglycosylated proteins. Our experiments are consistent 
with the current understanding of how this class is processed by 
Hrd3p binds misfolded CPY* with or without its glycans (Gauss   
et al., 2006a). Thus, Hrd3p is the best candidate as the sub-
strate receptor for the glycan-independent luminal pathway.   
The further addition of Yos9p adapts the complex to rec-
ognize glycan-dependent substrates (Buschhorn et al., 2004; 
Bhamidipati et al., 2005; Kim et al., 2005; Szathmary et al., 2005). 
The requirement for Der1p and Usa1p indicates that both lu-
minal substrate classes share the same processing mechanism 
after recognition. Therefore, it is not surprising that the patho-
genic protein cholera toxin has coopted this pathway for its   
cytosolic entry from the ER (Bernardi et al., 2008). Collectively, 
the  Hrd1  core  complex  exhibits  remarkable  functional  plas-
ticity. The addition of three accessory factors, Der1p, Usa1p, 
and Yos9p, is sufficient to expand its client range from a one 
class to three. Indeed, recent studies have shown that the inclu-
sion of Usa1p alone extends the range of ERAD-M substrates 
processed by the Hrd1p complex (Horn et al., 2009; Carroll 
and Hampton, 2010). This theme is expanded in the mamma-
lian system. The Yos9p homologues OS-9, XTP3-B, and their   
variants display substrate specificities that may be used to   
further diversify the substrate range (Christianson et al., 2008; 
Hosokawa et al., 2008).
Substrates display specific signals 
recognized by ERAD
One of the longstanding questions of ERQC revolves around 
the molecular cues used to differentiate folded, actively folding, 
Figure 5.  PrA contains a distinct determinant for glycan-independent ERAD. (A) Schematic representation of PrA*-GI variants. N-linked glycans are repre-
sented by branched symbols, signal sequences are shaded dark gray, prodomains are colored light gray, and positions of HA epitope tags are indicated. 
Dashed lines mark deleted regions. (B, C, and E–G) Substrate decay rates were measured and presented as described in Fig. 1 B. Strains and substrates 
are indicated. (B) PrA*-GI decay rates in wild-type (WT), htm1, and hrd1 cells. (C) Degradation profiles for PrA*-GI1, PrA*-GI2, PrA*-GI3, or 
PrA*-GI4 in wild-type cells. (D) Intracellular localization of PrA*-GI4 in wild-type cells was analyzed by confocal microscopy. The substrate was detected 
using anti-HA antibodies (green), the ER was visualized using anti-Kar2p antisera (red), and nuclei were stained by DAPI. Bar, 5 µM. (E) Wild-type and 
htm1 cells expressing PrA*-GI4CHO. (F) Wild-type, hrd1, usa1, and der1 cells expressing PrA-CTD. (G) Wild-type, yos9, and htm1 cells express-
ing PrA-CTD. Error bars indicate SEM.713 Modularity of an ERAD receptor complex • Kanehara et al.
YOS9 promoter was described previously (Kim et al., 2005). HA epitope 
tag was deleted from it by site-directed mutagenesis using KKN303 primer 
to create the plasmid pKK278. Plasmid pKK284, carrying Yos9R200A 
driven by the endogenous YOS9 promoter, was created by site-directed 
mutagenesis to make a point mutation R200A using KKN306 primer. Plasmid 
pKK278 was used as template for site-directed mutagenesis.
CPY* expression vector
Plasmid pKK286, carrying CPY* driven by a galactose-inducible promoter, 
was created by site-directed mutagenesis to delete HA epitope tag sequence 
from plasmid pES67 using KKN307 primer (Spear and Ng, 2003).
Hmg2p expression vector
Plasmid pRH244 was provided by R. Hampton (University of California, 
San Diego, La Jolla, CA). The following plasmids were generated using site-
directed mutagenesis of ERAD substrate clones (Sawano and Miyawaki, 
2000). Substrate variant names are indicated in parentheses. Primer   
sequences are listed in Table S4. All substrate genes are controlled by the 
endogenous promoter and encode the HA epitope tag at their C termini.
pKK214 (PrA*-AbD147–183/295–331). Using the KKN136 primer, a 
segment encoding Thr295 through Arg331 was deleted from pKK159.
pKK232 (PrA*-GI). Using the KKN228 primer, the N-linked glycosylation 
site was mutagenized on pKK214.
pWX41 (PrA*-GID1). Using the WXN41 primer, a segment encoding 
Lys23 through Leu71 was deleted from pKK232.
pWX29 (PrA*-GID2). Using the WXN29 primer, a segment encoding 
Asp72 through Ala142 was deleted from pKK232.
pWX30 (PrA*-GID3). Using the WXN30 primer, a segment encoding 
Glu143 through Glu213 was deleted from pKK232.
pWX31 (PrA*-GID4). Using the WXN31 primer, a segment encoding 
Ser214 through Ile284 was deleted from pKK232.
pWX51 (PrA*-GID4CHO). Using the WXN31 primer, a segment encoding 
Ser214 through Ile284 was deleted from pKK214.
pKK252 (PrA-CTD). Using the KKN279 primer, a segment encoding 
Lys26 through Ile284 was deleted from pKK150.
Indirect immunofluorescence
Strains were grown to early log phase in synthetic complete media lacking 
the appropriate component for plasmid selection. Formaldehyde (analyti-
cal grade; Merck) was added directly to 3–9 ml medium to 3.7% at 30°C 
for 90 min. After fixation, cells were collected by centrifugation and washed 
with 5 ml ice-cold 0.1 M potassium phosphate buffer, pH 7.5, for 5 min. 
Cells were resuspended and incubated in 90 µl 0.1 M potassium phos-
phate buffer, pH 7.5, containing 1.2 M sorbitol and 1 mg/ml zymolyase 
20T (United States Biological Inc.) for 10–20 min at room temperature to 
digest the cell wall.
To terminate digestion, cells were washed twice in 0.1 M potassium 
phosphate buffer, pH 7.5, containing 1.2 M sorbitol. Cells were resus-
pended in 30 µl 0.1 M potassium phosphate buffer, pH 7.5, containing 
1.2 M sorbitol and applied to a clean glass slide (precoated with 0.1% 
poly L-lysine) for 10 min at room temperature. Slides were washed once 
with ice-cold TBS buffer (50 mM Tris–HCl and 150 mM NaCl, pH 7.4) for 
3 min, soaked in methanol (20°C) for 6 min followed by acetone for 30 s,   
rinsed in ice-cold TBS buffer for 3 min, and air dried. Subsequent steps 
were performed at room temperature. 30 µl of blocking buffer (TBS buffer 
with 5% nonfat milk and 0.05% Tween 20) was added to each well and 
incubated for 30 min followed by a TBS buffer wash for 10 min. Primary 
antibodies HA.11 mAb (Covance) and polyclonal rabbit -Kar2p were 
applied at 1:500 and 1:1,000 dilutions, respectively, in 30 µl of blocking 
buffer for 90 min. Wells were washed twice for 10 min with TBS buffer. 
30 µl of blocking buffer containing Alexa Fluor 488 goat anti–mouse and 
Alexa Fluor 594 goat anti–rabbit (Invitrogen) as secondary antibodies was 
added to each well and incubated for 90 min in the dark. Slides were 
washed for 10 min twice with TBS buffer. Each well was applied with   
15  µl  of  mounting  medium  (PBS  buffer,  pH  9.0,  90%  glycerol,  and   
0.05 µg/ml DAPI) and a glass coverslip. Slides were sealed with clear nail 
polish and stored at 20°C in a dry and dark container.
Cells were visualized using an inverted microscope (LSM 510 META; 
Carl Zeiss, Inc.) with a Plan Apochromat 100× 1.4 NA Ph3 objective (Carl 
Zeiss, Inc.) in immersion oil (Immersol 518F; Carl Zeiss, Inc.) at room tempera-
ture. Image acquisition was performed using standard photomultiplier tube 
with LSM 510. Images were archived using LSM 5 Image Examiner (Carl 
Zeiss, Inc.) and Photoshop (version 7.0; Adobe), and no additional software 
adjustments were performed on images after acquisition other than cropping.
the mammalian Hrd1 pathway (Okuda-Shimizu and Hendershot, 
2007; Hosokawa et al., 2008). Therefore, it is likely that the 
advances represented by this study are also applicable to mam-
mals. The discovery of the glycan-independent mode of ERAD-L 
also shows that budding yeast have at least two distinct mech-
anisms for soluble, nonglycosylated substrates, one ubiquitin 
dependent and another ubiquitin independent (for review see 
Nakatsukasa and Brodsky, 2008). Although not fully charac-
terized, there are indications of a similar arrangement in mammals. 
Evidence of a mammalian ubiquitin-independent mechanism 
comes from detailed analysis using an elegant cell-free system. 
In this assay, the yeast gppF substrate undergoes retrotranslo-
cation across ER membranes independently of ubiquitination 
and p97 (the Cdc48p orthologue; Wahlman et al., 2007). This 
result indicates that the structural cues used to sort this sub-
strate in yeast are faithfully recognized in mammals and strength-
ens the view that ERQC mechanisms use specific determinants 
embedded in substrates to signal degradation if misfolded.
Concluding remarks
The ERAD client portfolio is perhaps the most varied among 
quality control systems. To tackle the challenge, substrate re-
ceptor sites have evolved to handle the topological diversity of 
substrates. It is now clear that the clearance of defective mole-
cules is caused by signals embedded within the substrates them-
selves. Molecules not bearing features recognized by ERAD but 
are nevertheless misfolded may be handled by alternative path-
ways. Some use ubiquitin-independent mechanisms of ERAD 
and others are sent to the vacuole (the yeast lysosome) through 
autophagy or via the classical secretory pathway (Chang and 
Fink, 1995; Hong et al., 1996; Jenness et al., 1997; VanSlyke et al., 
2000; Ravikumar et al., 2002; Kruse et al., 2006; Sarkar et al., 
2007). Understanding how these molecules are differentiated 
from folded proteins remains a major target for future studies.
Materials and methods
Strains and antibodies
Saccharomyces cerevisiae strains used in this study are listed in Tables 
S3 and S4. Anti-HA (HA.11) antibody, HA probe, and anti-Myc anti-
body  were  purchased  from  Covance.  Anti-hexokinase  antibody  was 
purchased from United States Biological Inc. Anti-Kar2p rabbit poly-
clonal antiserum was provided by P. Walter (University of California, 
San Francisco, San Francisco, CA).
Plasmids used in this study
Plasmids and primers used in this study are listed in Table S2. Plasmids 
were constructed using standard cloning protocols. All coding sequences 
of constructs used in this study were sequenced in their entirety. Unless 
indicated, all substrate proteins described in this study contain a single   
C-terminal HA epitope tag used for detection (Spear and Ng, 2005).
PrA expression vectors and variants
Plasmids pKK129, pKK159, pKK163, and pKK261 carry PrA*-Ab, PrA*-
Ab147–183, PrA*-Ab295–331, and ngPrA295–331 driven by their 
endogenous promoter, respectively, were described previously (Xie et al., 
2009). Plasmid pKK249, carrying ngPrA*295–331, was created as fol-
lows: a 1.6-kb fragment encoding PrA*-Ab and its promoter was released 
from plasmid pKK150 by digesting with ClaI. This fragment was ligated 
into pKK163 digested with ClaI to create pKK249.
Yos9 and Yos9R200A expression vectors
Plasmid pKK278, carrying Yos9 driven by its endogenous promoter, was 
created as follows: HA epitope–tagged Yos9p driven by the endogenous JCB • VOLUME 188 • NUMBER 5 • 2010   714
and 1 mM PMSF on ice for 1 h. The solubilized microsome fraction was 
collected by ultracentrifugation (30,000 g for 10 min). 50 µl agarose-
immobilized anti-HA antibody (Santa Cruz Biotechnology, Inc.) was added 
to the supernatant and incubated at 4°C with rocking for 2 h. The beads 
were washed gently three times in ice-cold Tris–IP buffer with 0.5% Triton   
X-100 and once in ice-cold Tris–IP buffer. Proteins were eluted from the 
beads by boiling in SDS loading buffer. Proteins were boiled for 5 min, 
resolved by SDS-PAGE, and visualized by Coomassie brilliant blue stain-
ing. Protein bands were excised for in-gel trypsinization and identified by 
matrix-assisted laser desorption/ionization mass spectrometry/mass spec-
trometry (National University of Singapore Mass Spectrometry Laboratory). 
Analysis of ngPrA295–331-binding proteins is shown in Table S1.
Online supplemental material
Fig.  S1  shows  PrA  variants  with  reduced  dependence  on  the  glycan-
  dependent ERAD factor Htm1p for degradation. Fig. S2 shows the deg-
radation profile of the ERAD-M substrate Hmg2p (single Myc tagged).   
Table S1 lists the peptide mass data of the ngPrA295–331-binding pro-
tein. Tables S2–S4 list the strains, plasmids, and oligonucleotide primers 
used in this study. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200907055/DC1.
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